Literature DB >> 29808270

[No increased risk of severe infections under biologic therapies in psoriasis].

D Sossau1, A S Yazdi2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29808270     DOI： 10.1007/s00105-018-4209-3

Source DB:  PubMed          Journal:  Hautarzt        ISSN： 0017-8470            Impact factor:   0.751


× No keyword cloud information.
  4 in total

Review 1.  Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis.

Authors:  Jasvinder A Singh; Chris Cameron; Shahrzad Noorbaloochi; Tyler Cullis; Matthew Tucker; Robin Christensen; Elizabeth Tanjong Ghogomu; Doug Coyle; Tammy Clifford; Peter Tugwell; George A Wells
Journal:  Lancet       Date:  2015-05-11       Impact factor: 79.321

Review 2.  The Role of Biologic Therapies in Dermatology.

Authors:  Ramin Fathi; April Wang Armstrong
Journal:  Med Clin North Am       Date:  2015-09-02       Impact factor: 5.456

3.  Infections in Moderate to Severe Psoriasis Patients Treated with Biological Drugs Compared to Classic Systemic Drugs: Findings from the BIOBADADERM Registry.

Authors:  Paula Dávila-Seijo; Esteban Dauden; M A Descalzo; Gregorio Carretero; José-Manuel Carrascosa; Francisco Vanaclocha; Francisco-José Gómez-García; Pablo De la Cueva-Dobao; Enrique Herrera-Ceballos; Isabel Belinchón; José-Luis López-Estebaranz; Merce Alsina; José-Luis Sánchez-Carazo; Marta Ferrán; Rosa Torrado; Carlos Ferrandiz; Raquel Rivera; Mar Llamas; Rafael Jiménez-Puya; Ignacio García-Doval
Journal:  J Invest Dermatol       Date:  2016-09-25       Impact factor: 8.551

4.  Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly.

Authors:  James B Galloway; Kimme L Hyrich; Louise K Mercer; William G Dixon; Bo Fu; Andrew P Ustianowski; Kath D Watson; Mark Lunt; Deborah P M Symmons
Journal:  Rheumatology (Oxford)       Date:  2010-07-31       Impact factor: 7.580
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.